Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Seeks Japan Approval for Advanced Pancreatic, Prostate Cancer Companion Diagnostic

NEW YORK – Myriad Genetics said Monday that it has submitted a supplementary application to the Japanese Ministry of Health Labor and Welfare for use of its BRACAnalysis Diagnostic System as a companion diagnostic to identify patients with metastatic pancreatic or metastatic castration-resistant prostate cancer who have germline BRCA1 and BRCA2 mutations and may be candidates for targeted therapy with the PARP inhibitor olaparib (AstraZeneca's Lynparza), subject to regulatory approval.

BRACAnalysis classifies a patient’s clinically significant germline DNA sequence variations in the BRCA1 and BRCA2 genes.  

The BRACAnalysis Diagnostic System was previously approved in Japan to identify patients with ovarian or breast cancer who have a germline BRCA mutation and are eligible for Lynparza therapy. BRACAnalysis is the only germline test for BRCA1 and BRCA2 mutations to receive regulatory approval in Japan, Myriad noted.

"Today’s regulatory filing potentially will expand the approved indications for BRACAnalysis as a companion diagnostic test in Japan," Gary King, executive VP of international operations at Myriad, said in a statement.

Salt Lake City, Utah-based Myriad has partnered with Shinjuku-Ku, Japan-based SRL, a subsidiary of Miraca Group, to commercialize the BRACAnalysis Diagnostic System in Japan.

Lynparza is marketed by Cambridge, UK-based AstraZeneca and Kenilworth, New Jersey-based MSD, also known as Merck in the US and Canada.

Myriad estimates there are more than 78,000 cases of prostate cancer and 40,000 cases of pancreatic cancer per year in Japan.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.